FDA Seeks Public Input on Adaptive AI Medical Devices That Can Change Their Answers (Updated 2026)
OVERVIEWThe FDA is actively seeking stakeholder input on how to regulate adaptive AI medical devices that can modify their outputs, recommendations, or decision logic after initial authorization based on new data or clinical feedback. This represents a fundamental regulatory challenge—traditional device approval models assume fixed functionality, but adaptive AI systems intentionally evolve. Key questions include how to establish appropriate performance boundaries for adaptive systems, what monitoring mechanisms ensure safety as systems change, and how to balance innovation speed with patient protection. The FDA's approach will likely emphasize pre-market validation of adaptation mechanisms, robust post-market surveillance, and transparent disclosure to clinicians about when and how AI systems have adapted. Healthcare organizations and AI developers should engage in FDA comment processes, provide evidence about safe adaptation practices, and help establish regulatory standards that enable responsible innovation. The resolution of adaptive AI regulation will significantly affect healthcare AI development timelines and deployment strategies for the next decade.
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.